FINWIRES · TerminalLIVE
FINWIRES

BP's Turnaround Gains Momentum on Debt Reduction, Cost Cuts, RBC Says

By

BP's (BP) "turnaround" is gaining momentum as stronger commodity conditions, asset sales and "cost reductions" are expected to accelerate debt reduction and improve the company's balance sheet, RBC Capital Markets said in a report Friday, after hosting a session with BP Chief Financial Officer Kate Thomson.

The firm expects BP's "all-in" liabilities to fall to about $34 billion by year-end from $54 billion in Q2, helped by the expected closing of the $6 billion Castrol deal. BP could reach its reported net debt target by the end of 2026, a year earlier than previously targeted, and could be in a position to restart share buybacks by mid-2027.

RBC also raised its earnings estimates to reflect stronger "refining margins" and expects Q3 net income of about $6.5 billion on a "mark-to-market" basis, compared with consensus of $4.3 billion, the report said.

The brokerage said BP's "improved balance sheet" should support upstream growth, while Thomson and management are expected to continue cutting costs, with "structural cost savings" now anticipated to reach $5.8 billion by the end of 2027, according to the report.

RBC has an outperform rating on BP with a price target of 700 British pence, saying the company remains in the "early stages of its turnaround" and that further asset sales, efficiency gains and a greater focus on its core oil and gas business could support additional upside.

Price: $43.92, Change: $+0.34, Percent Change: +0.78%

Related Articles

Wire

Vaxcyte Names New Medical and Legal Chiefs Ahead of Key Phase 3 Data

Vaxcyte (PCVX) appointed Luis Jodar as chief medical officer and David McAvoy as chief legal officer, the company said on Thursday.Jodar spent 17 years at Pfizer (PFE), most recently as senior vice president and chief medical officer for Vaccines and Infectious Diseases, the company said.McAvoy joins the company from Teva Pharmaceutical (TEVA), according to a statement.The vaccine developer also said it now expects to report topline data from its phase 3 OPUS-1 trial of VAX-31 in adults by the end of October, narrowing its previous guidance of a Q4 data release.

$PCVX
Wire

eGain Fiscal Q4 Adjusted Earnings, Revenue Fall; Shares Slump After Hours

EGain (EGAN) reported fiscal Q4 adjusted earnings late Thursday of $0.08 per diluted share, down from $0.09 a year earlier.Three analysts polled by FactSet projected $0.03.Revenue in the three months ended June 30 fell to $22.2 million from $23.2 million a year earlier.Three analysts projected $21.7 million.The company expects fiscal Q1 adjusted EPS of $0.05 to $0.08 on revenue of $20.9 million to $21.4 million. Three analysts project EPS of $0.08 on revenue of $22.3 million.For fiscal 2027, eGain expects adjusted EPS of $0.04 to $0.07 on revenue of $84.5 million to $86 million. Three analysts project EPS of $0.43 on revenue of $94.1 million.EGain shares slumped 29% in after-hours trading.

$EGAN
Wire

American Outdoor Brands Fiscal Q1 Swings to Adjusted Earnings, Revenue Rises

American Outdoor Brands (AOUT) reported fiscal Q1 non-GAAP earnings late Thursday of $0.03 per diluted share, swinging from a loss $0.26 year earlier.Two analysts polled by FactSet expected a loss of $0.24.Net sales for the quarter ended July 31 were $37.3 million, up from $29.7 million a year earlier.Two analysts expected $35.6 million.For fiscal 2027, the company maintained its net sales forecast of $200 million to $210 million. Two analysts expect $205.1 million.Shares of the company rose over 16% in after-hours trading.

$AOUT